Apple's Foldable iPhone Faces Engineering Setbacks, Mass Production Timeline at Risk 
Deere & Company Agrees to $99 Million Settlement Over Right-to-Repair Dispute 
First Western Ship Transits Strait of Hormuz Since Iran War Began 
Elon Musk Ties SpaceX IPO Access to Mandatory Grok AI Subscriptions 
UPS and Teamsters Reach Agreement to Limit Driver Severance Program 
TSMC Japan's Second Fab to Produce 3nm Chips by 2028 
SpaceX IPO: Retail Investors to Play Historic Role in Record-Breaking Public Offering 
Alibaba Shares Slide as Jefferies Slashes Price Target Over AI Spending and Business Losses 
U.S. Automakers Push Back Against EU Rules Blocking American Trucks from European Market 
Britain Courts Anthropic Amid US Defense Department Dispute 
Pony.ai, Uber, and Verne Launch Europe's First Commercial Robotaxi Service in Zagreb 
China Vanke Seeks Bond Extension Amid Mounting Debt Crisis 
Trump Administration Plans 100% Tariffs on Pharmaceutical Imports 
Anthropic Fights Pentagon Blacklisting in Dual Federal Court Battles 
Private Credit Under Pressure: Is a Slow-Motion Crisis Unfolding? 
MATCH Act Targets ASML and Chinese Chipmakers in New U.S. Export Crackdown 
ATLANTA, Sept. 06, 2016 -- Aviragen Therapeutics, Inc. (NASDAQ:AVIR) (formerly Biota Pharmaceuticals, Inc.), a pharmaceutical company that is developing the next generation of antivirals, announced today that the Company has granted two new hires options to purchase an aggregate of 125,000 shares of the Company's common stock with a per share exercise price of $1.33, the closing price on August 31, 2016. The stock options have a ten-year term and vests over a period of four years, with one-fourth vesting on the first anniversary of the grant date and one-fourth vesting on each of the three succeeding anniversaries. The option is subject to the terms and conditions of the Company's 2007 Omnibus Equity and Incentive Plan and the stock option agreement pursuant to which the option is granted.
The stock option was granted as an inducement material to the new employees entering into employment with Aviragen Therapeutics in accordance with NASDAQ Listing Rule 5635(c)(4).
About Aviragen Therapeutics, Inc.
Aviragen Therapeutics is focused on the discovery and development of the next generation of direct-acting antivirals to treat infections that have limited therapeutic options and affect a significant number of patients globally. The Company has three product candidates in active clinical development: These include vapendavir, an oral treatment for human rhinovirus upper (HRV) respiratory infections in moderate-to-severe asthmatics currently being evaluated in the Phase 2b SPIRITUS trial; BTA585, an oral fusion protein inhibitor that has received Fast Track designation by the U.S. FDA, in Phase 2 development for the treatment and prevention of respiratory syncytial virus (RSV) infections; and BTA074, a topical antiviral treatment in Phase 2 development for condyloma caused by human papillomavirus types 6 & 11. For additional information about the Company, please visit www.aviragentherapeutics.com.
Contacts: Mark Colonnese Executive Vice President and Chief Financial Officer Aviragen Therapeutics, Inc. (678) 221-3381 [email protected] Beth DelGiacco Stern Investor Relations, Inc. (212) 362-1200 [email protected]
